Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
OBJECTIVE
To evaluate prospectively the prognostic power of urinary nuclear matrix protein-22 (NMP-22) for bladder cancer in Taiwanese screening and surveillance settings.


METHODS
Single voided urine samples were obtained from 68 healthy individuals, 303 patients with benign urothelial diseases, and 28 patients with urogenital tumors. The NMP-22 levels in the urine samples were measured using enzyme-linked immunosorbent assay methods.


RESULTS
The median NMP-22 level in healthy individuals and patients with benign and malignant disease was 5.9, 4.8, and 7.4 U/mL, respectively. The positive NMP-22 rate in healthy individuals and patients with benign and malignant disease was 4.4%, 17.2%, and 50%, respectively. The sensitivity, specificity, positive predictive value, and negative predictive value was 50%, 82.8%, 21.2%, and 94.7%, respectively, using 7.5 U/mL as the cutoff value.


CONCLUSIONS
Our data demonstrated that NMP-22 is not a good diagnostic tool for screening or follow-up surveillance of bladder cancer owing to its low sensitivity and positive predictive value. Nevertheless, it could be adopted as a tool to rule out the possibility or risk of developing bladder cancer because of its high negative predictive value in our study.
Chang
Yih-Hsin
YH
School of Medical Technology, Chung Shan Medical University, Taichung, Taiwan, Republic of China.
Wu
Cheng-Hua
CH
Lee
Yao-Ling
YL
Huang
Po-Hsuan
PH
Kao
Yu-Lin
YL
Shiau
Ming-Yuh
MY
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000652:urine*; D002277:Carcinoma / Q000175:diagnosis / Q000652:urine*; D002648:Child; D002675:Child, Preschool; D003558:Cystoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000652:urine*; D009687:Nuclear Proteins / Q000652:urine*; D011237:Predictive Value of Tests; D011470:Prostatic Hyperplasia / Q000652:urine; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000652:urine*; D014556:Urine / Q000166:cytology; D014565:Urogenital Neoplasms / Q000175:diagnosis / Q000652:urine*; D014570:Urologic Diseases / Q000652:urine
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22